Back to Search
Start Over
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
- Source :
-
New England Journal of Medicine . 11/8/2018, Vol. 379 Issue 19, p1811-1822. 12p. - Publication Year :
- 2018
-
Abstract
- <bold>Background: </bold>The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma. The immunomodulatory agent pomalidomide plus dexamethasone has been shown to be effective in patients with multiple myeloma that is refractory to lenalidomide and a proteasome inhibitor.<bold>Methods: </bold>Patients with multiple myeloma that was refractory or relapsed and refractory to lenalidomide and a proteasome inhibitor were randomly assigned to receive elotuzumab plus pomalidomide and dexamethasone (elotuzumab group) or pomalidomide and dexamethasone alone (control group). The primary end point was investigator-assessed progression-free survival.<bold>Results: </bold>A total of 117 patients were randomly assigned to the elotuzumab group (60 patients) or the control group (57 patients). After a minimum follow-up period of 9.1 months, the median progression-free survival was 10.3 months in the elotuzumab group and 4.7 months in the control group. The hazard ratio for disease progression or death in the elotuzumab group as compared with the control group was 0.54 (95% confidence interval [CI], 0.34 to 0.86; P=0.008). The overall response rate was 53% in the elotuzumab group as compared with 26% in the control group (odds ratio, 3.25; 95% CI, 1.49 to 7.11). The most common grade 3 or 4 adverse events were neutropenia (13% in the elotuzumab group vs. 27% in the control group), anemia (10% vs. 20%), and hyperglycemia (8% vs. 7%). A total of 65% of the patients in each group had infections. Infusion reactions occurred in 3 patients (5%) in the elotuzumab group.<bold>Conclusions: </bold>Among patients with multiple myeloma in whom treatment with lenalidomide and a proteasome inhibitor had failed, the risk of progression or death was significantly lower among those who received elotuzumab plus pomalidomide and dexamethasone than among those who received pomalidomide plus dexamethasone alone. (Funded by Bristol-Myers Squibb and AbbVie Biotherapeutics; ELOQUENT-3 ClinicalTrials.gov number, NCT02654132 .). [ABSTRACT FROM AUTHOR]
- Subjects :
- *MULTIPLE myeloma
*DEXAMETHASONE
*PREGNANE
*DRUG therapy
*B cell lymphoma
*ANTINEOPLASTIC agents
*CLINICAL trials
*COMPARATIVE studies
*IMMUNOLOGICAL adjuvants
*INFECTION
*RESEARCH methodology
*MEDICAL cooperation
*MONOCLONAL antibodies
*NEUTROPENIA
*PROGNOSIS
*RESEARCH
*THALIDOMIDE
*EVALUATION research
*RANDOMIZED controlled trials
Subjects
Details
- Language :
- English
- ISSN :
- 00284793
- Volume :
- 379
- Issue :
- 19
- Database :
- Academic Search Index
- Journal :
- New England Journal of Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 133419233
- Full Text :
- https://doi.org/10.1056/NEJMoa1805762